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Abstract
Background: The Generation Scotland: Scottish Family Health Study (GS:SFHS) is a family-based population cohort
with DNA, biological samples, socio-demographic, psychological and clinical data from approximately 24,000 adult
volunteers across Scotland. Although data collection was cross-sectional, GS:SFHS became a prospective cohort due
to of the ability to link to routine Electronic Health Record (EHR) data. Over 20,000 participants were selected for
genotyping using a large genome-wide array.
Methods: GS:SFHS was analysed using genome-wide association studies (GWAS) to test the effects of a large spectrum
of variants, imputed using the Haplotype Research Consortium (HRC) dataset, on medically relevant traits measured
directly or obtained from EHRs. The HRC dataset is the largest available haplotype reference panel for imputation of
variants in populations of European ancestry and allows investigation of variants with low minor allele frequencies
within the entire GS:SFHS genotyped cohort.
Results: Genome-wide associations were run on 20,032 individuals using both genotyped and HRC imputed data. We
present results for a range of well-studied quantitative traits obtained from clinic visits and for serum urate measures
obtained from data linkage to EHRs collected by the Scottish National Health Service. Results replicated known
associations and additionally reveal novel findings, mainly with rare variants, validating the use of the HRC imputation
panel. For example, we identified two new associations with fasting glucose at variants near to Y_RNA and WDR4 and
four new associations with heart rate at SNPs within CSMD1 and ASPH, upstream of HTR1F and between PROKR2 and
GPCPD1. All were driven by rare variants (minor allele frequencies in the range of 0.08–1%). Proof of principle
for use of EHRs was verification of the highly significant association of urate levels with the well-established
urate transporter SLC2A9.
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Conclusions: GS:SFHS provides genetic data on over 20,000 participants alongside a range of phenotypes as
well as linkage to National Health Service laboratory and clinical records. We have shown that the combination of
deeper genotype imputation and extended phenotype availability make GS:SFHS an attractive resource to carry out
association studies to gain insight into the genetic architecture of complex traits.
Keywords: Genome-wide association studies (GWAS), Electronic health records, Imputation, Quantitative trait, Genetics,
Urate, Heart rate, Glucose, Haplotype Research Consortium (HRC)
Background
Generation Scotland is a multi-institution collaboration
that has created an ethically sound, family-based and
population-based resource for identifying the genetic
basis of common complex diseases [1–3]. The Scottish
Family Health Study component (GS:SFHS) has DNA and
sociodemographic, psychological and clinical data from
~24,000 adult volunteers from across Scotland. The ethni-
city of the cohort is 99% Caucasian, with 96% born in the
UK and 87% in Scotland. Features of GS:SFHS include the
family-based recruitment, breadth and depth of phenotype
information, ‘broad’ consent from participants to use their
data and samples for a wide range of medical research and
for re-contact, and consent and mechanisms for linkage of
all data to comprehensive routine healthcare records.
These features were designed to maximise the power of
the resource to identify, replicate or control for genetic
factors associated with a wide spectrum of illnesses and
risk factors [3].
GS:SFHS can also be utilised as a longitudinal cohort
due to the ability to link to routine Scottish National
Health Service (NHS) data. Electronic Health Record
(EHR) linkage uses the ten-digit community health index
(CHI) number, a unique identifying number allocated to
every person in Scotland registered with a General Practi-
tioner (GP), and used for all NHS procedures (registrations,
attendances, samples, prescribing and investigations). This
unique patient identifier allows healthcare records for indi-
viduals to be linked across time and location [4]. The
population is relatively stable with comparatively low levels
of geographic mobility and there is relatively little uptake
of private healthcare in the population. Few countries,
other than Scotland, have health service information which
combines high quality data, consistency, national coverage
and the ability to link data to allow for genetic and clinical
patient-based analysis and follow-up.
The Haplotype Reference Consortium (HRC) dataset
is a large haplotype reference panel for imputation of
genetic variants in populations of European ancestry,
recently made available to the research community [5].
Within a simulated genome-wide association study
(GWAS) dataset, it allowed an increased rate of accurate
imputation at minor allele frequencies as low as 0.1%,
which will allow better interrogation of genetic variation
across the allele spectrum. A selected subset of 428
GS:SFHS participants had their exomes sequenced at
high depth and contributed reference haplotypes to the
HRC dataset, making it ideal for more accurate imput-
ation of this cohort [6].
This paper describes genome-wide association analysis of
over 20,000 GS:SFHS participants using two genetic data-
sets (common, genotyped Single Nucleotide Polymorphisms
(SNPs) and HRC-imputed data) across a range of medically
relevant quantitative phenotypes measured at recruitment
in research clinics. To illustrate the quality and potential of
the many EHR linkage-derived phenotypes available, we
selected serum urate as an exemplar due to its direct associ-
ation with disease, gout, and its strong well-studied genetic
associations. About 10% of people with hyperuricemia
develop gout, an inflammatory arthritis that results from
deposition of monosodium urate crystals in the joint.
Genome-wide meta-analyses have identified 31 genome-
wide significant urate-associated SNPs, with SLC2A9 alone
explaining ~3% of the phenotypic variance [7].
Methods
Sample selection
Selection criteria for genome-wide genotype analysis of
the participants were: Caucasian ethnicity; born in the
UK (prioritising those born in Scotland); and full phenotype
data available from attendance at a Generation Scotland
research clinic. The participants were also selected to have
consented for their data to be linkable to their NHS
electronic medical records using the CHI number. The
GS:SFHS genotyped set consisted of 20,195 participants,
before quality control exclusions.
DNA extraction and genotyping
Blood (or occasionally saliva) samples from GS:SFHS
participants were collected, processed and stored using
standard operating procedures and managed through a
laboratory information management system at the
Edinburgh Clinical Research Facility, University of
Edinburgh [8]. DNA was quantitated using picogreen
and diluted to 50 ng/μL; 4 μL were then used in geno-
typing. The genotyping of the first 9863 samples used
the Illumina HumanOmniExpressExome-8 v1.0 BeadChip
and the remainder were genotyped using the Illumina
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HumanOmniExpressExome-8 v1.2 BeadChip, with Infi-
nium chemistry for both [9].
Phenotype measures
Measurement of total cholesterol, HDL cholesterol, urea
and creatinine was from serum prepared from 5 mL of
venous blood collected into a tube containing clot acti-
vator and gel separator at the time of the visit by the
participant to the research clinic. For glucose measure-
ment, 2 mL of venous blood was collected in a sodium
fluoride/potassium oxalate tube, with fasting duration
recorded. Resting heart rate (pulse) was recorded using
an Omron digital blood pressure monitor. Two readings
were taken and the second reading was used in the ana-
lyses. All other cardiometabolic and anthropometric pheno-
type measures (see Table 1) are described in [3].
The EHR biochemistry dataset was extracted on 28th
September 2015 and covers 11,125 participants. EHR data
are held in the Tayside Safe Haven, which is fully accredited
and utilises a VMware Horizon client environment. Data
are placed on a server within a secure IT environment,
where the data user is given secure remote access for its
analysis [4]. For serum urate, records were available from
October 1988 to August 2015. Any data entries in the EHR
relating to pregnancy (keywords one or more of ‘pregna/
labour/GEST/PET’, total of 117 entries in the urate data-
set), were manually removed, as data obtained during preg-
nancy are usually not included in a GWAS. Many of the
participant IDs have multiple readings, spread over time.
For extraction of serum urate data for analysis, the highest
reading was used, as a high reading would trigger a treat-
ment (such as allopurinol) to lower the urate level, which is
then checked by the clinician requesting a subsequent test.
Genotype data quality control
Genotyping quality control was performed using the fol-
lowing procedures: individuals with a call rate less than
98% were removed, as were SNPs with a call rate less than
98% or Hardy-Weinberg equilibrium p value less than 1 ×
10–6. Mendelian errors, determined using relationships
recorded in the pedigree, were removed by setting the
individual-level genotypes at erroneous SNPs to missing.
Ancestry outliers who were more than six standard devia-
tions away from the mean, in a principal component ana-
lysis of GS:SFHS [10] merged with 1092 individuals from
the 1000 Genomes Project [11], were excluded. A total of
20,032 individuals (8227 male participants and 11,805
female participants) passed all quality control thresh-
olds. The number of genotyped autosomal SNPs that
passed all quality control parameters was 604,858.
Pedigree correction
Sample identity was verified by comparing the genetic
and recorded gender in the first instance and pedigrees
were checked for unknown or incorrectly recorded rela-
tionships based on estimated genome-wide identity-by-
descent (IBD).
Unrecorded first-degree or second degree relationships
(calculated IBD ≥ 25%) were identified and entered into
the pedigree. Pedigree links to first-degree or second-
degree relatives were broken or adjusted if the difference
between the calculated and expected amount of IBD
was ≥ 25%. After these corrections, any remaining pedi-
gree outliers as determined by examination of the plots
of expected versus observed IBD sharing were identified
and corrected in the pedigree. Due to some missing par-
ental genotypes, autosomal SNP sharing was not always
enough to unambiguously determine whether individuals
were related through the maternal or paternal line. In
such cases, mitochondrial and/or Y-chromosome markers
were compared to help determine the correct lineage.
The full pedigree contains 42,662 individuals (22,383
female participants) in 6863 families, across five genera-
tions (average 2.34 generations per family). Family sizes
were in the range of 1–66 individuals, with an average of
6.22 individuals per family. The final genotyped dataset
contains 9853 parent–child pairs, 8495 full siblings (52
monozygotic twins), 381 half siblings, 848 grandparent–
grandchild pairs, 2443 first cousins and 6599 avuncular
(niece/nephew–aunt/uncle) relationships.
Imputation
In order to increase the density of variants throughout
the genome, the genotyped data were imputed utilising
the Sanger Imputation Service [12] using the HRC panel
v1.1 [5, 13]. This exome sequence data will have greatly
improved imputation quality across the whole cohort.
Autosomal haplotypes were checked to ensure consistency
with the reference panel (strand orientation, reference
allele, position) then pre-phased using Shapeit2 v2r837
[14, 15] using the Shapeit2 duohmm option11 [16], taking
advantage of the cohort family structure in order to
improve the imputation quality [17]. Monogenic and low
imputation quality (INFO < 0.4) variants were removed
from the imputed dataset leaving 24,111,857 variants
available for downstream analysis.
Phenotype quality control and exclusions
Prior to analysis, extreme outliers (those with values
more than three times the interquartile distances away
from either the 75th or the 25th percentile values) were
removed for each phenotypic measure to account for er-
rors in quantification and to remove individuals not rep-
resentative of normal variation within the population.
Approximately 4000 glucose measures were from people
who had not fasted for at least 4 h, so these were ex-
cluded from the fasting glucose analysis. Additionally,
948 individuals were identified as having diabetes, as
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Table 1 Top GWAS hits
Baseline characteristic N dbSNP ID Minor allele
frequency
p value Gene Imputation
quality
Gene association
reported previously?
Region significant in
genotyped data?
Cardiometabolic
Diastolic blood pressure 19,546 rs142892876 0.0010 4.97E-08 CNTN6 0.75 No No
rs528908640 0.0005 1.93E-08 OPA1 0.80 No No
rs568998724 0.0007 2.91E-08 - 0.78 No No
rs187680191 0.0006 2.94E-09 NRG4 0.51 No No
Systolic blood pressure 19,547 None None
Pulse pressure 19,546 None None
Heart rate 19,920 rs9970334 0.4474 4.38E-08 ICMT 0.90 Yes No
rs755291044 0.0017 1.80E-08 - 0.90 No No
rs145669495 0.0022 2.01E-08 CSMD1 0.90 No No
rs142916219 0.0037 2.21E-08 ASPH 0.85 No No
rs365990 0.3637 4.04E-10 MYH6 0.99 Yes GWS
rs148397504 0.0008 3.21E-09 - 0.45 No No
Biochemistry
Serum creatinine 16,347 rs548873184 0.0010 1.47E-08 LINC00626 0.96 No No
rs573421908 0.0027 1.35E-08 SLC35F3 0.80 Yes No
rs62412107 0.0660 1.87E-08 - 0.79 No No
rs3812036 0.2301 1.13E-10 SLC34A1 0.96 Yes GWS
Fasting plasma glucose
(with diabetics)
16,174 rs560887 0.2907 6.02E-68 G6PC2 1.00 Yes GWS
rs9873618 0.2871 9.83E-12 SLC2A2 0.99 Yes GWS
rs917793 0.1831 2.51E-24 YKT6 0.98 Yes GWS
rs13266634 0.3153 3.66E-11 SLC30A8 1.00 Yes GWS
rs533883198 0.0027 3.86E-08 - 0.84 No No
rs7981781 0.2337 1.40E-08 PDX1 0.98 Yes GWS
rs370189685 0.0014 7.32E-09 WDR4 0.63 No No
Fasting plasma glucose
(diabetics removed)
15,226 rs79687284 0.0364 1.87E-08 - 0.78 Yes GWS
rs780095 0.4267 8.20E-09 GCKR 1.00 Yes GWS
rs560887 0.2907 2.09E-75 G6PC2 1.00 Yes GWS
rs8192675 0.2839 8.41E-11 SLC2A2 1.00 Yes GWS
rs917793 0.1831 1.46E-28 YKT6 0.98 Yes GWS
rs11558471 0.3227 4.63E-13 SLC30A8 1.00 Yes GWS
rs143399767 0.0108 1.42E-08 Y_RNA 0.89 No No
rs7981781 0.2337 5.01E-10 PDX1 0.98 Yes GWS
rs370189685 0.0014 2.75E-08 WDR4 0.63 No Suggestive
HDL cholesterol 19,223 rs149963466 0.0016 3.18E-08 - 0.76 No No
rs76183280 0.0048 4.14E-08 AC016735.2 0.78 No No
rs4841132 0.0925 1.08E-08 RP11-115 J16.1 1.00 Yes Suggestive
rs15285 0.2675 1.16E-18 LPL 1.00 Yes GWS
rs2740488 0.2745 2.53E-08 ABCA1 1.00 Yes GWS
rs138326449 0.0032 2.92E-20 APOC3 0.85 Yes No
rs114529226 0.0038 6.98E-09 IGHVII-33-1 0.64 No No
rs261290 0.3442 2.78E-25 ALDH1A2 1.00 Yes GWS
rs3764261 0.3261 1.40E-113 CETP 1.00 Yes GWS
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Table 1 Top GWAS hits (Continued)
rs143264468 0.0010 1.99E-09 LRRC29 0.81 Yes Suggestive
rs72836561 0.0294 1.55E-11 CD300LG 0.87 Yes No
rs149615216 0.0119 3.20E-09 LIPG 0.97 Yes Suggestive
rs116843064 0.0230 5.57E-10 ANGPTL4 0.84 Yes No
rs7412 0.0779 5.95E-14 APOE 0.98 Yes GWS
rs453755 0.2480 3.22E-08 LILRA3 0.92 Yes No
rs435306 0.2547 2.87E-08 PLTP 1.00 Yes Suggestive
Cholesterol 19,259 rs11591147 0.0169 1.83E-17 PCSK9 0.98 Yes GWS
rs10889333 0.3601 2.12E-10 DOCK7 1.00 Yes GWS
rs12740374 0.2288 8.19E-22 CELSR2 1.00 Yes GWS
rs672889 0.1356 3.77E-16 - 1.00 Yes GWS
rs75331444 0.0720 1.87E-11 ABCG8 0.99 Yes GWS
rs12916 0.3970 6.35E-11 HMGCR 0.99 Yes GWS
rs74617384 0.0838 3.02E-09 LPA 0.93 Yes No
rs4841133 0.0929 2.51E-09 RP11-115 J16.1 1.00 Yes Suggestive
rs2000999 0.1776 7.01E-09 HPR 0.99 Yes Suggestive
rs10412048 0.1086 5.00E-25 - 0.98 Yes GWS
rs7412 0.0779 5.22E-94 APOE 0.98 Yes GWS
Urea 19,293 rs760077 0.4247 6.24E-09 MTX1 0.98 Yes Suggestive
rs16862780 0.1574 3.03E-10 RP11-132 N15.3 1.00 Yes GWS
rs112647987 0.0680 3.07E-08 - 0.99 No No
rs6950388 0.1872 1.57E-08 UNCX 0.95 Yes GWS
rs10224210 0.2799 5.71E-09 PRKAG2 0.92 Yes Suggestive
Anthropometric
Body mass index 19900 rs73139123 0.1830 1.34E-09 - 0.96 Yes GWS
rs10498218 0.0012 3.98E-08 COL4A4 0.84 Yes No
rs149913955 0.0059 2.18E-08 RP11-624 L4.1 0.74 No No
rs571835655 0.0011 6.61E-09 - 0.82 No No
rs55872725 0.3951 5.71E-21 FTO 1.00 Yes GWS
Height 19,965 rs146949893 0.0031 4.49E-08 RP1-35C21.2 0.72 No No
rs558671668 0.0062 2.53E-08 RP11-317P15.6 0.80 No No
rs6765866 0.0007 2.05E-08 CMTM8 0.59 No No
rs1991431 0.4338 5.25E-13 ZBTB38 1.00 Yes GWS
rs35362908 0.1006 7.04E-09 LCORL 0.73 Yes No
rs552283803 0.0016 3.99E-08 ARHGAP24 0.79 No No
rs755546258 0.0007 2.58E-08 DAP 0.72 No No
rs72742734 0.0537 3.61E-08 NPR3 1.00 Yes Suggestive
rs554379257 0.0006 4.83E-08 CTD-2023 N9.1 0.44 No No
rs7766641 0.2551 3.32E-13 HIST1H2BE 1.00 Yes GWS
rs57026767 0.1550 4.50E-11 C6orf1 1.00 Yes GWS
rs566773279 0.0005 1.17E-08 - 0.69 No No
rs1490384 0.4851 7.09E-10 - 1.00 Yes GWS
rs7753012 0.3072 7.60E-14 GPR126 0.99 Yes GWS
rs184469050 0.0088 1.58E-08 - 0.89 No No
rs144225905 0.0010 2.13E-09 - 0.46 No No
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determined from self-reporting at the time of sample col-
lection or from EHR-extracted diagnosis of diabetes at any
time. Apparent non-diabetics with glucose measures >
7 mmol/L were also removed. Analysis of glucose was
performed on both the full fasting dataset and the same
dataset excluding diabetics and high glucose outliers.
Heritability
Heritabilities were estimated for the same phenotype
values that were used to run the GWAS. The ‘polygenic’
command in SOLAR version 8.1.1 [18] was used to esti-
mate heritability based on the social pedigrees (no gen-
etic information was used here). The ‘polygenic’
command in the GenABEL R package [19] was used to
calculate genetic kinship-based heritability. The standard
errors for this latter heritability estimate were obtained
by re-running the ‘polygenic’ command and fixing the
heritability to 0. The difference between the two estimates
yields a one-sided test with a Chi-square distribution with
one degree of freedom.
Genome-wide associations
Genome-wide associations were performed on both ge-
notyped and imputed data. For the HRC-imputed data,
only results from variants with a minor allele count of
20 in our sample (or minor allele frequency [MAF] of
0.05%) were considered. For the common variant geno-
typed data, no MAF cutoff was used. For each pheno-
type, an additive model for the fitted SNP fixed effect
was set up incorporating the same covariates as described
in the relevant published meta-analyses or by direct as-
sessment where no prior meta-analysis analysis plan was
available (full details in Additional file 1: Table S1) and a
random polygenic effect accounting for relatedness among
participants. Some phenotypes (as indicated in Additional
file 1: Table S1) were inverse-normal transformed to
Table 1 Top GWAS hits (Continued)
rs7952436 0.0896 1.91E-12 KDM2A 0.88 Yes No
rs634552 0.1365 2.30E-08 SERPINH1 0.98 Yes GWS
rs76895963 0.0285 3.43E-08 CCND2 0.78 Yes [48, 49] No
rs770307181 0.0005 1.09E-08 - 0.50 No No
rs139770682 0.0005 4.55E-08 - 0.72 No No
rs11614062 0.1943 2.09E-08 SOCS2-AS1 0.99 Yes GWS
rs75061684 0.0006 5.33E-10 - 0.49 No No
rs16942323 0.0344 1.09E-11 ACAN 0.93 Yes No
rs8096254 0.2598 4.32E-12 CABLES1 1.00 Yes GWS
rs6060402 0.3585 2.80E-13 - 0.98 Yes GWS
Waist-to-hip ratio 19,695 rs72959041 0.0566 2.54E-14 RSPO3 0.90 Yes Suggestive
rs149924309 0.0023 3.70E-08 - 0.81 No No
rs187209742 0.0023 4.91E-08 SERPINA10 0.70 No No
rs751156121 0.0006 1.29E-08 - 0.78 No No
Body fat 19,480 rs10921288 0.0235 1.04E-08 - 0.99 No GWS
rs142101835 0.0022 3.25E-08 IRS1 0.69 Yes No
rs560546550 0.0007 3.17E-09 WDR41 0.89 No No
rs571835655 0.0011 2.03E-08 - 0.82 No No
rs55872725 0.3951 5.55E-16 FTO 1.00 Yes GWS
rs141793746 0.0030 3.31E-08 DYM 0.86 No No
NHS EHR linkage
Serum urate 2077 rs6449213 0.1652 1.93E-17 SLC2A9 1.00 Yes GWS
rs75869162 0.0054 1.57E-08 FAM134B 0.80 No No
rs141208451 0.0053 3.13E-09 RP11-430H10.4 0.86 No No
rs187171029 0.0060 1.84E-08 ZNF160 0.91 No No
Summary of the baseline characteristics of the GS:SFHS sub-cohort of 20,032 analysed by GWAS, with genome-wide significant markers from the imputed GWAS
listed. We indicate known associations in published research or present in the NHGRI GWAS Catalog within 100 kb of the sentinal SNP reported here. The column
called ‘Region significant in genotyped data?’ indicates whether any SNPs within 500 kb of the reported SNP reach genome-wide significance (GWS, p < 5*10–8) or
suggestive significance (Suggestive, p < 10–5) in the genotyped data
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ensure normal distribution of the model’s residuals, using
the ‘rntransform’ function in the GenABEL R package
[19]. Different GWAS analysis programs were used for the
genotype and imputed data to utilise available computa-
tional resources most efficiently, but both pipelines ac-
count for relatedness.
For the genotype data, the ‘mmscore’ function of Gen-
ABEL was used for the genome-wide association test
under an additive model. This score test for family-based
association takes into account relationship structure and
allows unbiased estimations of SNP allelic effect when re-
latedness is present between individuals. The relationship
matrix used in this analysis was generated by the ‘ibs’
function of GenABEL (using weight = ‘freq’ option), which
uses genomic data to estimate the realized pair-wise
kinship coefficients.
Due to their larger size, the sets of associations with
the HRC imputed variants were performed with the soft-
ware RegScan v0.2 [20]. The pgresidualY estimated from
the polygenic function in GenABEL was used for associ-
ation analysis. The effect size, standard errors and p values
were thereafter corrected to account for relatedness using
the GRAMMAR-Gamma factors also provided by the
‘polygenic’ function [21]. The significance threshold for
the genotype and imputed data was set at p < 5 × 10–8.
Results
Heritability
Genetic and social pedigree-based heritabilities were es-
timated for the phenotypes detailed in Table 1 and are
shown in Additional file 2: Figure S1 and Additional file 1:
Table S2, along with heritabilities previously described for
the same traits (where available) in the literature. The her-
itabilities of our phenotypes are generally in alignment
with those quoted in the literature, except for pulse pres-
sure, whose heritability in our data (0.13, SE 0.01) is ap-
proximately half of the heritability quoted in the literature
(0.24, SE 0.08) [22]. Conversely, our estimates of the
heritability of serum creatinine (0.44, SE 0.01) are more
than twice the heritability quoted in the literature
(0.19, SE 0.07) [23].
Genome-wide association studies
We selected four cardiometabolic, six biochemical and
four anthropometric quantitative traits to evaluate GWAS
outputs from: (1) directly genotyped and (2) HRC-
imputed data. The chosen traits are diastolic blood pres-
sure, systolic blood pressure, pulse pressure, heart rate,
serum creatinine, fasting plasma glucose, HDL cholesterol,
total cholesterol, urea, urate, body mass index, height,
waist-to-hip ratio and body fat percentage. The majority
of these traits have strong genetic associations when
analysed within large multi-cohort meta-analyses,
therefore, any genome-wide associations detected in
the GS:SFHS cohort can be compared with the estab-
lished body of knowledge.
Sentinel variants for all the independent genome-wide
significant association signals for each phenotype are
listed in Table 1, together with their imputation quality
if they were not directly genotyped and whether an asso-
ciation signal had previously been reported within
±500 kb. All significant findings were checked against
the National Human Genome Research Institute cata-
logue of published GWAS [24] and, if not present there,
were searched for in published papers and other online
resources. All SNPs showing trait associations exceeding
the threshold for genome-wide significance are reported
in Additional files 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14
and in Miami plots, with results using the directly geno-
typed and HRC-imputed data opposing each other to re-
flect the gain brought by imputation (Additional file 2:
Figures S2–S14). The Q-Q plots for all analyses are
shown in Additional file 2: Figure S15 with inflation
factors reported in Additional file 1: Table S3. No
phenotype showed significant inflation, indicating that
correction for stratification has been adequately applied.
Multiple, previously identified, significant findings were
obtained for all of the traits except for blood pressure
measures (Table 1), validating the quality of both the
genotypic and the phenotypic data in GS:SFHS. We
identified 37 new independent associations across 12 of
the 14 selected research clinic-measured phenotypes in-
cluding four for diastolic blood pressure. Only four of
the sentinel SNPs for the novel signals had a MAF
greater than 1% (range: 1.08–6.8%); all others are rare,
including 13 very rare with MAF < 10–3. All but one
(rs10921288, MAF = 0.0235, associated with body fat %)
were not directly genotyped. In contrast, of the sentinel
SNPs in already reported associated regions, only five
had a MAF lower than 1%. These include a previously
reported replicated association with the same rare vari-
ant, the APOC3 splice variant rs138326449 associated
with HDL cholesterol [25].
Taking advantage of the availability of pedigrees for
GS:SFHS, we looked at whether some of the rare imputed
variants are distributed randomly in the population or
whether they segregate within families and related individ-
uals. These results are presented in Additional file 1: Table
S4 and support a clustering of these variants in families.
In Figs. 1 and 2, the results of the GWAS with fasting
plasma glucose and resting heart rate, respectively, are
depicted in more detail using Miami plots. We identified
two novel associations in fasting glucose (Table 2),
rs143399767, 2.7 kb upstream of Y_RNA, a non-coding
RNA which mainly associates with RNA-binding pro-
teins like Ro-60 and insulin-like growth factor 2 messen-
ger RNA binding protein 1 (IGF2BP1) in cytoplasmic
ribonucleoprotein complexes [26] and rs370189685 is
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within an intronic variant of WD repeat domain 4
(WDR4), a gene which codes for a transfer RNA-modifying
enzyme Both of these are rare variants (minor allele
frequencies of 1.08% and 0.1%, respectively). We also
replicated known associations in GCKR, G6PC2,
SLC2A2, YKT6, SLC30A8 and PDX1. We identified
four new associations with heart rate (Table 3):
rs145669495, a CSMD1 intronic variant; rs142916219,
a ASPH intronic variant; and two associations with
rs755291044 and rs148397504 in intergenic regions.
We additionally replicated known associations at
ICMT and MYH6. The estimated effects of the associ-
ated variants in GS:SFHS are shown in Tables 2 and 3
and are compared to those of top hits reported in the
Fig. 1 Miami plot of fasting plasma glucose. The top panel shows the GWAS results using all SNPs imputed to the HRC reference panel, while the
bottom panel shows only directly genotyped SNPs. In the Miami plot − log10 (p value) is plotted on the y-axis and chromosomal location is plotted
on the x-axis. The genome-wide significance threshold after correction for multiple testing (p value < 5 × 10–8) is indicated by a dark grey dashed line,
while suggestive significance (p value < 10–5) is indicated by a light grey dashed line. The # symbol denotes a hit in an intergenic region. Red arrows
indicate SNPs that are not plotted because they have a high –log10 (p value) (indicated in brackets)
Fig. 2 Miami plot of resting heart rate. The top panel shows the GWAS results using all SNPs imputed to the HRC reference panel, while the bottom
panel shows only directly genotyped SNPs. In the Miami plot − log10 (p value) is plotted on the y-axis and chromosomal location is plotted on the
x-axis. The genome-wide significance threshold after correction for multiple testing (p value < 5 × 10–8) is indicated by a dark grey dashed
line, while suggestive significance (p value < 10–5) is indicated by a light grey dashed line. The # symbol denotes a hit in an intergenic region
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meta-analysis summary files (glucose) [27] or the
GWAS catalogue (heart rate), respectively. The SNP
MAFs from GS:SFHS are also compared against those
in the HRC imputation panel.
GWAS of serum urate extracted from electronic health
records
In the 11,125 individuals with NHS EHR biochemistry
available, there are 2356 GS:SFHS participants with
serum urate measured at least once and a total of 6268
tests. The proportion of participants who have had at
least one test recorded for urate is 21%. Of these partici-
pants, 214 have been identified as having taken allopurinol,
a urate-lowering medication, either through self-reporting
at GS:SFHS clinic visit or through NHS prescription data
linkage. The highest urate measure from all individuals
was used for GWAS.
The GWAS for urate was performed using both
genotype and imputed data, taking into account the
sex of the participant and adjusting for participant
age at the time of the test. The results of these analyses
are displayed in Fig. 3. In both analyses, the association
with the lowest p value was at the well-established
SLC2A9 locus and the most significant SNP was
rs6449213 with a p value of 7.2 × 10–17 in the genotype
data and 5.13 × 10–17 in the imputed data (Table 4, Fig. 3).
This was the only locus reaching genome-wide signifi-
cance for this trait in the genotyped analysis. Addition-
ally, three loci exceeded our threshold for significance
in the imputed analysis – the sentinal SNPs are
rs75869162 in RP11-260E18.1-001 (a long non-coding
RNA of unknown function), rs141208451 in RP11-
958 J22.2 (a novel processed transcript) and RP11-
430H10.4 (a long non-coding RNA of unknown func-
tion); and rs187171029, an intronic variant in
ZNF160. All of these new associations are with rare
variants (MAF < 1%, range: 0.53–0.6%) not present in
the results of the largest serum urate GWAS from
the Global Urate Genomics Consortium (GUGC) [28]
(Additional file 1: Table S5).
Discussion
The continued improvement in scale and coverage of
haplotype reference panels for use in imputation has
opened possibilities for exploration of the contribution
of low frequency and rare variants to traits previously
Table 2 Fasting glucose top hits
Gene SNP Chr Position Effect
allele
GS minor allele
frequency
HRC
MAF
GS
p value
GS effect
size
Meta top
SNP
Meta
p value
GS and meta
SNP R2
GS and meta
SNP D’
PROX1-AS1 rs79687284 1 214150821 C 0.036 0.0306 1.87E-08 0.20 rs340874 6.80E-08 0.02 0.99
GCKR rs780095 2 27741105 G 0.427 0.4516 8.20E-09 0.07 rs1260326 1.26E-24 0.72 0.93
G6PC2 rs560887* 2 169763148 C 0.291 0.2861 2.09E-75 0.24 rs560887 4.68E-100 1 1
SLC2A2 rs8192675 3 170724883 C 0.284 0.3067 8.41E-11 –0.09 rs11920090 1.90E-11 0.32 0.99
YKT6 rs917793 7 44245853 T 0.183 0.1766 1.46E-28 0.17 rs4607517 1.39E-51 1 1
SLC30A8 rs11558471* 8 118185733 G 0.323 0.3129 4.63E-13 –0.09 rs11558471 3.96E-21 1 1
Y_RNA rs143399767 9 96182703 C 0.011 0.0160 1.42E-08 0.36 NA NA NA NA
PDX1 rs7981781 13 28499962 A 0.234 0.2296 5.01E-10 0.09 rs2293941 2.93E-08 0.99 0.99
WDR4 rs370189685 21 44276432 C 0.001 0.0009 2.75E-08 –1.15 NA NA NA NA
Summary of top hits of the imputed GWAS analysis of fasting plasma glucose (15,226 people after those with diabetes were removed) in Generation
Scotland, compared with top hits in a meta-analysis reported in [50]. Starred (*) SNPs indicate the same SNP in the GS and meta-analysis datasets. En-
tries in bold are within 500,000 bases of a SNP that reached genome-wide significance in the genotyped GWAS analysis. Entries with missing
meta-analysis top SNPs (indicated by NA) are novel associations that did not reach significance in the meta-analysis
Table 3 Heart rate top hits
Gene SNP Chr Position Effect
allele
GS minor allele
frequency
HRC
MAF
GS
p value
GS effect
size
GWAS catalog
top SNP
GWAS catalog
p value
GS and meta
SNP R2
GS and meta
SNP D’
ICMT rs9970334 1 6296238 G 0.447 0.4502 4.38E-08 0.70 rs846111 7.00E-40 [51] 0.47 0.98
- rs755291044 3 87751558 A 0.002 - 1.80E-08 8.60 NA NA NA NA
CSMD1 rs145669495 8 4102424 G 0.002 0.0024 2.01E-08 7.66 NA NA NA NA
ASPH rs142916219 8 62481520 G 0.004 0.0022 2.21E-08 5.97 NA NA NA NA
MYH6 rs365990* 14 23861811 G 0.364 0.3644 4.04E-10 0.78 rs365990 5.00E-45 [52] 1 1
- rs148397504 20 5376623 A 0.001 0.0006 3.21E-09 18.54 NA NA NA NA
Summary of top hits of the imputed GWAS analysis of heart rate in 19,920 Generation Scotland participants, compared with associations reported in
the GWAS catalogue. The starred (*) SNP indicates the same SNP in the GS and GWAS catalogue. Entries in bold are within 500,000 bases of a SNP that
reached genome-wide significance in the genotyped GWAS analysis. Entries with missing GWAS catalogue top SNPs (indicated by NAs) are novel associations
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analysed in GWAS [25, 29], where the contribution of
common variation is better known.
We investigated the use of the recently released
HRC imputation set to perform GWAS in a large study
of > 20,000 individuals from the GS:SFHS cohort, illustrat-
ing both the promise and the challenge of such studies.
Study advantages
This analysis is performed on the largest single homoge-
neous population sample, to date. We detected most
known genetic associations with common variants
(MAF > 5%) using the genotyped dataset alone. For many
of these associations, a weaker signal was detected using
the genotyped GWAS, which became stronger in imputed
SNPs that are presumably more closely linked to the
causal variant. We identify such associations in many of
the traits reported in Table 1 and the majority are within a
known association signal.
The pedigree-based heritability estimates are slightly
higher than the heritabilities estimated using the genetic
data, which could be because the genotype-based herit-
ability estimation only considers additive genetic effects
(but not dominant or epistatic effects). Additionally,
the pedigree-based heritability might be capturing the
effects of a shared environment between family mem-
bers living in the same household, which can inflate
the heritability estimates.
Imputated data generated most of the association signals
with low frequency and rare variants. We investigated, in
greater detail, the biological relevance of the associations
detected in heart rate.
We identified four new associations with heart rate
(Table 3). rs755291044 is located 300 kb upstream of the
nearest gene, 5-Hydroxytryptamine Receptor 1 F (HTR1F),
which codes for a subunit of the serotonin receptor. Sero-
tonin (5-hydroxytryptamine) is known to modulate heart
Fig. 3 Miami plot of uric acid. The top panel shows the GWAS results using all SNPs imputed to the HRC reference panel, while the bottom panel
shows only directly genotyped SNPs. In the Miami plot− log10 (p value) is plotted on the y-axis and chromosomal location is plotted on the x-axis.
The genome-wide significance threshold after correction for multiple testing (p value < 5 × 10–8) is indicated by a dark grey dashed line, while
suggestive significance (p value < 10–5) is indicated by a light grey dashed line
Table 4 Uric acid top hits
Gene SNP Chr Position Effect allele GS minor allele
frequency
HRC MAF GS p value GS effect
size
Meta top
SNP
Meta p value
SLC2A9 rs6449213 4 9994215 T 0.165 0.1857 1.93E-17 0.592 rs12498742 <1 E − 700
FAM134B rs75869162 5 16617922 A 0.005 0.0019 1.57E-08 2.24 rs386845 1.18E-02
RP11-430H10.4 rs141208451 11 45538920 A 0.005 0.0011 3.13E-09 2.32 rs11038475 7.36E-03
ZNF160 rs187171029 19 53599256 T 0.006 0.0040 1.84E-08 2 rs16984293 2.58E-02
Summary of top hits of the imputed GWAS analysis of uric acid in 2077 Generation Scotland participants, compared with top hits in a meta-analysis reported in
the GUGC. Top hits were extracted from the region within 100,000 bases of the imputed GWAS top SNP. Entries in bold are within 500,000 bases of a SNP that
reached genome-wide significance in the genotyped GWAS analysis
Nagy et al. Genome Medicine  (2017) 9:23 Page 10 of 14
rate and blood pressure through direct vascular effects and
indirectly through the sympathetic nervous system [30].
Intronic variant rs145669495 is within the CUB and
Sushi Multiple Domains 1 gene (CSMD1), which has a re-
ported association with blood pressure in a Korean cohort
[31]. While there is only a weak epidemiological correlation
between heart rate and blood pressure, it is interesting that
we find two genetic loci that affect both phenotypes.
rs142916219 lies within an intron of the Aspartate
Beta-Hydroxylate/Junctin gene (ASPH), which is a regu-
lator of calcium homeostasis. Some isoforms encoded by
this gene localize to the sarcoplasmic reticulum, which is
the smooth endoplasmic reticulum found in muscle tissue
(including heart muscle). The relationship between cal-
cium concentration and (heart) muscle contraction is well
documented [32] and reductions in the level of ASPH
have been linked to heart failure and arrhythmia [33].
rs148397504 is 80 kb upstream of the Prokineticin
Receptor 2 gene (PROKR2) and 150 kb downstream of
the glycerophosphocholine Phosphodiesterase 1 gene
(GPCPD1), within a CTCF binding site. PROKR2 encodes
a receptor for prokineticin, a secreted protein that pro-
motes angiogenesis [34] and heart development [35]. Acti-
vation of this receptor leads to calcium mobilization and
PROKR1, a paralog with unusually high sequence similar-
ity to this receptor, has been associated with insulin-
mediated Akt signalling and myocardial fibrosis, diastolic
dysfunction and impaired capillary formation [36, 37].
GPCPD1 (formerly GDE5), the upstream gene, is
highly expressed in the fetal heart and is involved in
skeletal muscle differentiation [38]. We note that this
variant has a low imputation quality (0.44), so this asso-
ciation should be treated with caution until it is repli-
cated in another study or is confirmed through direct
sequencing in carriers.
It is encouraging that these novel associations lie
within, or near, genes that are known, or suspected, to
affect cardiac muscle function and morphology, blood
pressure and heart rate.
We note that an association which reached genome-
wide significance in the genotype data (rs6127466, p =
4.58 × 10–8) drops to just below the threshold in the
HRC-imputed data (p = 7.27 × 10–8). This SNP lies within
the KIAA1755 gene, which has been found to associate
with heart rate in the GWAS catalogue. During quality
control, five individuals had their genotypes set to missing
at this SNP. These individuals’ genotypes were then im-
puted, allowing them to be included in the analysis and
subsequently altering the p value of the association.
We also show here the validity of phenotypes derived
from electronic health records in GS:SFHS. The value of
EHRs in genomics research is becoming widely recog-
nised (e.g. [39, 40]). The focus to date has largely been
on genetic associations with International Classification
of Disease (ICD-9 or ICD-10) codes which are available
in most EHR systems but successful GWAS of several
liver biochemistry measures in 3294 samples from the
eMERGE network have recently been described [41].
The anticipated GWAS hits in SLC2A9 were found for
serum urate in this project and validate this EHR data
resource as a valuable method of acquiring additional
phenotypes for the GS:SFHS cohort. We did not detect
significant effects from other known urate loci, such as
ABCG2, but this is not entirely surprising given that our
sample size is much smaller than most consortium
meta-analyses. However, the majority show comparable
effect size and direction (Additional file 2: Figure S16).
We did, however, detect three new loci with signals
driven by rare variants (Table 4).
As well as linking to routine biochemistry, linkage can
be made to hospital inpatient episode data (Scottish
Morbidity Record, SMR01; ICD-10 codes) and to pre-
scribing data, providing multiple opportunities to further
exploit this approach.
Limitations
Validation of rare variant imputation
Most of the low frequency and rare variants were im-
puted and absent from the genotyping arrays and would
need to be validated by direct genotyping. We found
that the associated rare variants tended to cluster within
related individuals, as up to 90% (and on average, 55%)
of the carriers of each rare variant reported for heart
rate, fasting glucose and serum urate shares a kinship
coefficient of greater than 0.05 (are fourth-degree rela-
tives) with at least one other carrier. In fact, most of
these pairs of carriers have a kinship coefficient ≥ 0.25
(second-degree relatives) and are assigned to the same
family in the pedigree file. This gives some support to
the validity of these variants and illustrates the advan-
tage gained by imputing into family-based cohorts. The
splice variant rs138326449 (MAF 0.032% in GS:SFHS) in
the APOC3 gene has been validated in a pioneering
GWAS UK10K study that first report its association with
HDL cholesterol, plasma triglycerides and VLDL levels
in the ALSPAC and TwinsUK cohorts [25]. Four other
rare variants—rs142101835 (IRS1), associated with body
fat; rs143264468 (LRRC29), associated with HDL choles-
terol; rs10498218 (COL4A4), associated with BMI; and
rs573421908 (SLC35F3), associated with serum creatini-
ne—also replicated in our study. In addition, two of the
novel loci associated with diastolic blood pressure in our
study have been implicated in clinical studies. Polymor-
phisms in mitochondrial dynamin like GTPase (OPA1)
were reported to have an age-dependent association with
blood pressure and hypertension in a Korean population
[42]. Low levels of serum Neuregulin 4 (NRG4) were re-
cently shown to be strongly associated with elevated
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blood pressure and fasting glucose in a Chinese study of
over 1200 obese adults [43].
Validation of novel association
We used a threshold for genome-wide significance of
5 × 10–8, as a more stringent one based on the number
of independent variants tested and number of traits
tested would leave very few of the previously described
association signals, listed in Table 1, reaching genome-
wide significance while most of those (admittedly those
driven by the common variants) have been well repli-
cated in large studies. It is clear that a proportion of the
results reported here will be false positives and all novel
associations will need replication.
For a more global assessment of our data quality we
compared the alleles reported in GS:SFHS HRC imputed
data versus the available high quality exome chip data
for the same samples (52,007 overlapping SNPs with
[maf > = 5e-4]) and found high levels of agreement and a
concordance of 95.3% for all SNPs, 98.4% concordance
for SNP with a MAF > = 0.01 (20,012 SNPs) and 89% for
rarer SNPs (frequency < 0.01) (31,995 SNPs). We have
also checked for concordance for the genome-wide sig-
nificant hits found in our association studies with the
available exome sequence data from 864 individuals in
GS:SFHS and identified 20 SNPS, all of which had a con-
cordance of at least 97%. Unfortunately, only two rare
variants identified in our GWAS—rs142101835 (IRS1)
and rs138326449 (APOC3)—were among these 20 SNPs.
We also made a further attempt to confirm some add-
itional novel variants by checking HRC-imputed results
from two other cohorts (ORCADES and VHS) (http://
www.orcades.ed.ac.uk/orcades/VHSS.html), but because
of the considerably smaller sample sizes (~2000 in each
cohort) no rare variants were sufficiently frequent to
establish a replication.
Replication in other populations may be difficult for the
rare variants because variants such as these of large effect
will be kept at low frequency and not found in other dis-
parate populations by the effects of natural selection,
which are likely much more pronounced on large effects
than on small. However, the precedent of replication of
the APOC3 variant rs138326449 is promising and very
large study in the UK (such as UKBiobank) where similar
imputations will be performed are soon to be available.
Conclusions
Here, we present the first detailed description of the entire
GS:SFHS GWAS dataset. While a subset of Generation
Scotland has already served as a valuable co-discovery and
replication cohort for genetic associations for a range of
traits (e.g. [44–46]), here we demonstrate the stand-alone
value of the full cohort through replication of established
genetic associations, as well as through the discovery of
several novel associations. Although not presented here,
the family-based structure of GS:SFHS allows the shared
variation between individuals within families to be disen-
tangled into its genetic and environmental components
(e.g. [47]).With the growing emphasis on the use of rou-
tine administrative health data, studies such as this project
become increasingly important in order to provide infor-
mation on the accuracy and validity of other findings that
are based on EHRs.
This dataset is now available for collaborative studies
and meta-analyses that are consistent with the original
‘broad’ consent [2].
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